Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

920
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
920
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

855
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
855
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

659
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
659
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

1.4K
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

627
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
627
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

606
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
606

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gastric GIST with life-threatening anaemia and paraganglioma: a rare presentation of suspected Carney-Stratakis syndrome in a young adult.

Journal of surgical case reports·2026
Same author

Multidisciplinary management of refractory malignant upper gastrointestinal bleeding in metastatic gastric adenocarcinoma.

BMJ case reports·2026
Same author

Esophageal Squamous Papilloma: An Unusual Cause of Dysphagia.

Cureus·2026
Same author

GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study.

Scientific reports·2026
Same author

Bevacizumab as Rescue Therapy for GI Bleeding in Hereditary Hemorrhagic Telangiectasia.

Cureus·2026
Same author

Unexplained Giant Esophageal Ulceration in a Pregnant Woman With Severe Immunosuppression.

Cureus·2026

Related Experiment Video

Updated: Mar 26, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K

Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.

Jagpal S Klair1, Mohit Girotra2,3, Laura F Hutchins2,4

  • 1Department of Internal Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA. klairjagpal@yahoo.com.

Digestive Diseases and Sciences
|February 6, 2016
PubMed
Summary

Ipilimumab, a melanoma treatment, can cause immune-related gastrointestinal toxicity. Early recognition and management of these side effects are crucial for patient outcomes.

Keywords:
ColitisIpilimumabMetastatic melanomaPerforation

Related Experiment Videos

Last Updated: Mar 26, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K

Area of Science:

  • Immunology
  • Oncology
  • Gastroenterology

Background:

  • Ipilimumab is an immune checkpoint inhibitor used for metastatic melanoma.
  • It offers survival benefits but can cause immune-related adverse effects (IRAEs).
  • Gastrointestinal toxicity is a significant concern with ipilimumab therapy.

Observation:

  • This case series details three metastatic melanoma patients treated with ipilimumab.
  • Patients presented with diverse gastrointestinal (GI) manifestations and complications.
  • Observed toxicities included diarrhea, colitis, and rare but severe events like bowel perforation.

Findings:

  • Ipilimumab-induced gastrointestinal toxicity (IGT) affects a significant percentage of patients.
  • Diarrhea and colitis are common, while bowel perforation and pancreatitis are less frequent but serious.
  • Prompt diagnosis and intervention are key to managing IGT.

Implications:

  • Gastroenterologists must be aware of the spectrum of IGT associated with ipilimumab.
  • Management strategies involve steroids, infliximab, and potentially surgery for severe complications.
  • Understanding and addressing IGT is vital for optimizing ipilimumab therapy in melanoma patients.